clobazam

Clobazam is a benzodiazepine anticonvulsant used primarily as adjunctive therapy to control seizures associated with Lennox-Gastaut syndrome (LGS) in adults and children aged two years and older. It acts by enhancing the effect of the inhibitory neurotransmitter gamma aminobutyric acid (GABA) at the GABA-A receptor in the brain, thereby reducing abnormal electrical activity that leads to seizures. Clobazam is classified as a central nervous system depressant and can also be used for other seizure types or anxiety disorders in some countries. It is available in oral formulations such as tablets, suspensions, and films[1][2][3][5]. The drug was first approved internationally in Australia in 1970 and has since been approved for use in over 100 countries[5]. In the United States, it received FDA approval for LGS-related seizures in October 2011[4]. Clobazam carries risks of dependence, withdrawal symptoms if stopped abruptly, serious skin reactions including DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), sedation, respiratory depression especially when combined with other CNS depressants or opioids[2][3].

Brand names

OnfiSympazan

Other names

氯巴占7-Chloro-1-methyl-5-phenyl-1H-1,5-benzodiazepine-2,4-(3H,5H)-dione